A Wu1, N H Andrew1, A Tsirbas2, P Tan3, A Gajdatsy3, D Selva1. 1. South Australian Institute of Ophthalmology, University of Adelaide, Adelaide, South Australia, Australia. 2. Sydney Eye Hospital, Sydney, New South Wales, Australia. 3. Lions Eye Institute, Perth, Western Australia, Australia.
Abstract
PURPOSE: To review the clinical efficacy and safety of rituximab for treatment of IgG4-related orbital disease (IgG4-ROD). DESIGN: Retrospective multicentre interventional case series. METHODS: Chart review for five cases of biopsy-confirmed IgG4-ROD (IgG4+>10/HPF, ratio of IgG4+/IgG+>40%) treated with rituximab. Information retrieved included the dosing schedule, adverse events and the magnitude, temporality, and duration of the clinical response. RESULTS: All cases of IgG4-ROD were either steroid dependent or steroid resistant. Rituximab doses for induction therapy included two doses of 1000 mg at 2-weekly intervals, and four doses at 375 mg/m(2) at weekly intervals. Two months after starting rituximab, three cases achieved complete clinical resolution and two cases achieved partial clinical resolution. Complete radiological resolution occurred in one case, and partial radiological resolution in three cases. Three cases received rituximab maintenance therapy and one case was commenced on mycophenolate. No relapse occurred during a mean follow-up of 33 months (range: 7-65 months). One disease relapse occurred when the dosing interval of rituximab maintenance therapy was extended to 6-monthly intervals; remission was swiftly achieved with rituximab reinduction therapy. The only adverse effects reported were one episode of fatigue lasting 1 week and two episodes of orbital discomfort. CONCLUSION: Rituximab may be an effective treatment option for IgG4-ROD that is steroid dependent or steroid intolerant. Rituximab therapy resulted in swift clinical and radiological improvement, many months free of relapse, and few side effects.
PURPOSE: To review the clinical efficacy and safety of rituximab for treatment of IgG4-related orbital disease (IgG4-ROD). DESIGN: Retrospective multicentre interventional case series. METHODS: Chart review for five cases of biopsy-confirmed IgG4-ROD (IgG4+>10/HPF, ratio of IgG4+/IgG+>40%) treated with rituximab. Information retrieved included the dosing schedule, adverse events and the magnitude, temporality, and duration of the clinical response. RESULTS: All cases of IgG4-ROD were either steroid dependent or steroid resistant. Rituximab doses for induction therapy included two doses of 1000 mg at 2-weekly intervals, and four doses at 375 mg/m(2) at weekly intervals. Two months after starting rituximab, three cases achieved complete clinical resolution and two cases achieved partial clinical resolution. Complete radiological resolution occurred in one case, and partial radiological resolution in three cases. Three cases received rituximab maintenance therapy and one case was commenced on mycophenolate. No relapse occurred during a mean follow-up of 33 months (range: 7-65 months). One disease relapse occurred when the dosing interval of rituximab maintenance therapy was extended to 6-monthly intervals; remission was swiftly achieved with rituximab reinduction therapy. The only adverse effects reported were one episode of fatigue lasting 1 week and two episodes of orbital discomfort. CONCLUSION:Rituximab may be an effective treatment option for IgG4-ROD that is steroid dependent or steroid intolerant. Rituximab therapy resulted in swift clinical and radiological improvement, many months free of relapse, and few side effects.
Authors: Chris Jalilian; H Miles Prince; Chris McCormack; Stephen Lade; Chan Y Cheah Journal: Australas J Dermatol Date: 2013-09-05 Impact factor: 2.875
Authors: Phil A Hart; Mark D Topazian; Thomas E Witzig; Jonathan E Clain; Ferga C Gleeson; Robin R Klebig; Michael J Levy; Randall K Pearson; Bret T Petersen; Thomas C Smyrk; Aravind Sugumar; Naoki Takahashi; Santhi S Vege; Suresh T Chari Journal: Gut Date: 2012-08-30 Impact factor: 23.059
Authors: Terumi Kamisawa; Suresh T Chari; Markus M Lerch; Myung-Hwan Kim; Thomas M Gress; Tooru Shimosegawa Journal: Gut Date: 2013-06-08 Impact factor: 23.059
Authors: Phil A Hart; Terumi Kamisawa; William R Brugge; Jae Bock Chung; Emma L Culver; László Czakó; Luca Frulloni; Vay Liang W Go; Thomas M Gress; Myung-Hwan Kim; Shigeyuki Kawa; Kyu Taek Lee; Markus M Lerch; Wei-Chih Liao; Matthias Löhr; Kazuichi Okazaki; Ji Kon Ryu; Nicolas Schleinitz; Kyoko Shimizu; Tooru Shimosegawa; Roy Soetikno; George Webster; Dhiraj Yadav; Yoh Zen; Suresh T Chari Journal: Gut Date: 2012-12-11 Impact factor: 23.059
Authors: Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane Journal: Ann Rheum Dis Date: 2012-11-07 Impact factor: 19.103
Authors: Teresa A Ferreira; P Saraiva; S W Genders; M V Buchem; G P M Luyten; J-W Beenakker Journal: Neuroradiology Date: 2018-10-11 Impact factor: 2.804
Authors: Pilar Brito-Zerón; Belchin Kostov; Xavier Bosch; Nihan Acar-Denizli; Manuel Ramos-Casals; John H Stone Journal: Medicine (Baltimore) Date: 2016-06 Impact factor: 1.889